Developer docs
API playgroundTry for free, no card

Search company profiles

Roche Sequencing

Full company profile

uuid000cqns

Namestring
Roche Sequencing
Legal namestring
F. Hoffmann-La Roche Ltd
Company typeenum
Public
Founded yearint
1896
Descriptiontext

Roche Sequencing is a product category within Roche Diagnostics, the diagnostics division of F. Hoffmann-La Roche Ltd (founded 1896, listed on the SIX Swiss Exchange under ROG). Headquartered in Basel, Switzerland, with North American operations in Pleasanton, California, the unit sells next-generation sequencing (NGS) solutions to research institutions, clinical laboratories, and pharmaceutical companies globally through Roche Diagnostics' direct enterprise sales force and online ordering portal.

The portfolio is organized as an end-to-end workflow. Sample preparation is anchored by KAPA library prep kits (EvoPrep, EvoPlus, RNA EvoPrep), KAPA HyperExome V2 target enrichment probes, and the HyperDesign custom panel design tool. The AVENIO Edge System provides walk-away IVD-grade automation for library prep, target enrichment, quantification, and pooling, while AVENIO Tumor Tissue CGP and ctDNA Expanded kits deliver oncology-focused comprehensive genomic profiling assays. Data analysis is handled by cloud software including navify Mutation Profiler for tertiary interpretation and the FoundationOne Analysis Platform for secondary analysis. The flagship strategic asset is the AXELIOS 1 Sequencing Platform — currently in development — built on proprietary Sequencing by Expansion (SBX) chemistry, positioned for high-accuracy, high-throughput Research Use Only sequencing with an SBX-Fast workflow targeting approximately 5 hours from sample to VCF.

The business model combines hardware sales (AXELIOS 1 sequencer, AVENIO Edge System) with recurring consumables revenue (KAPA kits, AVENIO assays) and cloud-based software subscriptions (navify, FoundationOne). Pricing is not publicly disclosed and is quote-based through Roche Diagnostics' commercial channels. GTM is enterprise field sales supported by technical specialists and an online service portal (eLabDoc). Distribution leverages Roche's global manufacturing footprint, and the unit is actively building an ecosystem through integrations with third-party automation vendors (Volta Labs) and co-development partners (Watchmaker Genomics). Specific revenue figures for Roche Sequencing are not publicly disclosed.

Short descriptiontext

Roche Sequencing is the next-generation sequencing product line within Roche Diagnostics, selling KAPA library prep, AVENIO assays and automation, navify and FoundationOne analysis software, and the in-development AXELIOS 1 sequencer based on proprietary Sequencing by Expansion chemistry to research, clinical, and pharma customers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIndianapolis, United States
HQ citystring
Indianapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
next-generation sequencing, NGS library preparation, target enrichment solutions, comprehensive genomic profiling, sequencing automation systems
Industry6 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Next-Generation Sequencing Solutions
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1NGS Instruments and Platforms
TypeHardware Sales
Description

Sale of sequencing instruments including the AXELIOS 1 platform (in development) and AVENIO Edge System automation hardware for IVD and research use.

diagnostics.roche.com
2Sequencing Reagents and Kits
TypeSubscription Recurring
Description

KAPA library preparation kits, target enrichment panels, and AVENIO CGP assay kits sold as recurring consumables for NGS workflows.

diagnostics.roche.com
3Software Licenses
TypeSubscription Recurring
Description

Cloud-based software solutions including navify Mutation Profiler, FoundationOne Analysis Platform, and AVENIO Oncology Analysis Software for data analysis.

diagnostics.roche.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1KAPA
Description

KAPA library preparation and target enrichment solutions for NGS workflows, including KAPA EvoPrep Kits, KAPA EvoPlus Kits, KAPA RNA EvoPrep Kits, and KAPA HyperExome V2 Probes.

diagnostics.roche.com
+4 more records
Core offering1 text field

Roche Sequencing sells an end-to-end next-generation sequencing (NGS) portfolio covering KAPA DNA/RNA library preparation kits, KAPA target enrichment panels and probes, the AVENIO Edge System for automated sample prep, AVENIO comprehensive genomic profiling assays for oncology research, cloud-based analysis software (navify Mutation Profiler, AVENIO Oncology Analysis Software, FoundationOne Analysis Platform), and the in-development AXELIOS 1 Sequencing Platform based on its proprietary Sequencing by Expansion (SBX) chemistry. Products are sold as instruments, recurring reagent/consumable kits, and software licenses to research institutions, clinical laboratories, and pharmaceutical companies worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • SBX-Fast workflow enables DNA sequencing from sample to VCF in approximately 5 hours
+2 more records
Product overview1 text field

Roche Sequencing offers a comprehensive portfolio of next-generation sequencing (NGS) solutions organized into integrated modules covering the entire sequencing workflow from sample preparation to data analysis. The portfolio is anchored by the KAPA library preparation and target enrichment solutions for efficient sample prep, the AVENIO Edge System for walk-away automation, AVENIO comprehensive genomic profiling (CGP) assays for oncology research, the AXELIOS 1 Sequencing Platform powered by proprietary Sequencing by Expansion (SBX) technology, and cloud-based data analysis tools including navify Mutation Profiler, AVENIO Oncology Analysis Software, and FoundationOne Analysis Platform. The AXELIOS 1 platform, based on innovative SBX technology, is designed to deliver unprecedented speed and flexibility for research applications. Third-party partnerships enable integration with external analysis platforms and liquid handling systems.

Product and service12 records
1KAPA EvoPrep Kits
CategoryNGS library preparation
Description

NGS library preparation kits that enable pre-fragmented DNA library preparation for whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted sequencing, and methyl-seq with a streamlined, fully automatable workflow. Targeted at research and clinical laboratories performing NGS workflows.

2KAPA EvoPlus Kits
CategoryNGS library preparation
Description

High-performance DNA library preparation kits with enhanced enzymatic fragmentation and a streamlined, fully automatable workflow, for laboratories requiring reliable NGS library prep.

3KAPA RNA EvoPrep Kits
CategoryNGS library preparation
Description

RNA library preparation kits designed to shorten workflow, boost sequencing efficiency, capture more unique transcripts, and accelerate RNA-based discovery research for genomics laboratories.

4KAPA HyperExome V2 Probes and Kits
CategoryNGS target enrichment
Description

Whole Exome Sequencing target enrichment probe and kit solution delivering superior content coverage for WES applications in research and clinical genomics.

5HyperDesign
CategoryNGS target enrichment
Description

Custom design tool for KAPA Target Enrichment workflows, combining KAPA target enrichment chemistry with Roche's probe and primer design expertise to design custom NGS panels.

6AVENIO Edge System
CategorySample prep automation
Description

Fully automated IVD liquid handler for end-to-end library preparation, target enrichment, quantification, normalization, and pooling, combining Roche NGS expertise with pre-analytical automation experience for clinical and research laboratories.

7AVENIO Designer
CategorySample prep automation
Description

Intuitive, templated design software for rapid and flexible user-defined workflow deployment on the AVENIO Edge System, with tunable parameters and validated workflows.

8AXELIOS 1 Sequencing Platform
CategoryNGS platform
Description

High-throughput, transformative Research Use Only (RUO) sequencing platform powered by Sequencing by Expansion (SBX) technology, delivering accurate, cost-effective sequencing across a wide range of research applications at unprecedented scale and speed. SBX-Fast workflow enables DNA sequencing from sample to VCF in approximately 5 hours.

9navify Mutation Profiler
CategoryNGS data analysis
Description

Research use only cloud-based software for interpretation of genomic alterations and signatures generated from sequencing DNA isolated from FFPE tumor tissue and liquid biopsy specimens, annotating somatic alterations with information from curated literature, databases, guidelines, drug labels, and clinical trials.

10AVENIO Tumor Tissue CGP Kit V2
CategoryNGS assay
Description

In-house next-generation sequencing (NGS) research assay providing comprehensive genomic profiling of solid tumors from formalin-fixed tissue specimens for oncology research.

11AVENIO Tumor Tissue CGP Automated Kit
CategoryNGS assay
Description

Next-generation sequencing (NGS) assay for comprehensive genomic profiling (CGP) of solid tumors with automated workflow on the AVENIO Edge System for oncology research laboratories.

12AVENIO ctDNA Expanded Kit V2
CategoryNGS assay
Description

NGS liquid biopsy research assay for lung cancer, colorectal cancer, and pan-cancer research using circulating tumor DNA from plasma.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-26
Description

Volta Labs announced integration of its Callisto platform with Roche Sequencing's AXELIOS 1 system at AGBT 2026. The integration enables automated genomics workflows combining Callisto's automation capabilities with Roche's SBX sequencing technology. UMC Utrecht and Hartwig Medical Foundation presented production-scale validation data showing thousands of patient samples processed with improved consistency and operational efficiency over nearly a year of deployment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Launched a PCR-free whole genome sequencing kit developed in collaboration with Watchmaker Genomics, expanding the ecosystem of solutions available for the Callisto platform and AXELIOS 1 system.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dominant short-read NGS platform provider (NovaSeq, NextSeq, iSeq) with a full sequencing-by-synthesis workflow; directly competes with Roche Sequencing's AXELIOS 1 and KAPA/AVENIO consumables for research and clinical lab customers.

TypeDirect peer
Description

Operates the Ion Torrent sequencing platform plus an extensive NGS reagents and target-enrichment portfolio (Ion AmpliSeq, Oncomine); competes head-to-head with Roche across sequencing instruments, library prep, and oncology assays.

TypeDirect peer
Description

Developer of the AVITI benchtop NGS platform using an alternative sequencing chemistry; targets many of the same translational and clinical research labs that Roche's AXELIOS 1 and KAPA reagents are pursuing.

TypeDirect peer
Description

Provides the G4 benchtop NGS sequencer with a unique four-flow-cell architecture, competing directly with Roche's modular/flexible sequencing pitch to mid-throughput research customers.

TypeDirect peer
Description

Long-read sequencing platform (Revio, Onso) now expanding into short-read oncology research, increasingly competing with Roche's NGS assays and AXELIOS 1 across translational genomics.

TypeDirect peer
Description

Long-read/native nucleic acid sequencing platform (PromethION, GridION) competing for translational and clinical research applications where Roche's KAPA HyperExome and AXELIOS 1 also compete for share.

TypeBroad incumbent
Description

Diversified sample-prep and molecular diagnostics provider (QIAseq target enrichment, GeneReader) overlapping with Roche's KAPA library prep, AVENIO assays, and bioinformatics offering.

TypeBroad incumbent
Description

Provides Droplet Digital PCR and life science research tools with adjacent NGS workflows; competes at the bench-research and translational lab level where Roche sells KAPA reagents.

TypeEmerging player
Description

Early-stage sequencing platform targeting ultra-low-cost high-throughput sequencing, positioning against AXELIOS 1 in the large-scale genomics research market.

10MGI Tech (BGI Group)
TypeEmerging player
Description

Provides DNBSEQ sequencing platforms and related reagents with broad global (especially APAC) reach; competes with Roche Sequencing instruments and consumables in international markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roche Sequencing

Next-Generation Sequencing Solutionssequencing.roche.com

Roche Sequencing is the next-generation sequencing product line within Roche Diagnostics, selling KAPA library prep, AVENIO assays and automation, navify and FoundationOne analysis software, and the in-development AXELIOS 1 sequencer based on proprietary Sequencing by Expansion chemistry to research, clinical, and pharma customers worldwide.

What Roche Sequencing does

Roche Sequencing is a product category within Roche Diagnostics, the diagnostics division of F. Hoffmann-La Roche Ltd (founded 1896, listed on the SIX Swiss Exchange under ROG). Headquartered in Basel, Switzerland, with North American operations in Pleasanton, California, the unit sells next-generation sequencing (NGS) solutions to research institutions, clinical laboratories, and pharmaceutical companies globally through Roche Diagnostics' direct enterprise sales force and online ordering portal.

The portfolio is organized as an end-to-end workflow. Sample preparation is anchored by KAPA library prep kits (EvoPrep, EvoPlus, RNA EvoPrep), KAPA HyperExome V2 target enrichment probes, and the HyperDesign custom panel design tool. The AVENIO Edge System provides walk-away IVD-grade automation for library prep, target enrichment, quantification, and pooling, while AVENIO Tumor Tissue CGP and ctDNA Expanded kits deliver oncology-focused comprehensive genomic profiling assays. Data analysis is handled by cloud software including navify Mutation Profiler for tertiary interpretation and the FoundationOne Analysis Platform for secondary analysis. The flagship strategic asset is the AXELIOS 1 Sequencing Platform — currently in development — built on proprietary Sequencing by Expansion (SBX) chemistry, positioned for high-accuracy, high-throughput Research Use Only sequencing with an SBX-Fast workflow targeting approximately 5 hours from sample to VCF.

The business model combines hardware sales (AXELIOS 1 sequencer, AVENIO Edge System) with recurring consumables revenue (KAPA kits, AVENIO assays) and cloud-based software subscriptions (navify, FoundationOne). Pricing is not publicly disclosed and is quote-based through Roche Diagnostics' commercial channels. GTM is enterprise field sales supported by technical specialists and an online service portal (eLabDoc). Distribution leverages Roche's global manufacturing footprint, and the unit is actively building an ecosystem through integrations with third-party automation vendors (Volta Labs) and co-development partners (Watchmaker Genomics). Specific revenue figures for Roche Sequencing are not publicly disclosed.

Roche Sequencing firmographics

Firmographics
Name
Roche Sequencing
Legal name
F. Hoffmann-La Roche Ltd
Website
https://sequencing.roche.com
Company type
Public
Founded year
1896
Operating status
Operating
Headcount range
101–250 employees
Short description
Roche Sequencing is the next-generation sequencing product line within Roche Diagnostics, selling KAPA library prep, AVENIO assays and automation, navify and FoundationOne analysis software, and the in-development AXELIOS 1 sequencer based on proprietary Sequencing by Expansion chemistry to research, clinical, and pharma customers worldwide.
Ownership category
akta.pro rank

Roche Sequencing industry classification

Industry
Product category
Next-Generation Sequencing Solutions
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)

Keywords

  • Next-generation sequencing
  • NGS library preparation
  • Target enrichment solutions
  • Comprehensive genomic profiling
  • Sequencing automation systems

Where Roche Sequencing is headquartered

Location

Headquarters

HQ city
Indianapolis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Roche Sequencing business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. NGS Instruments and Platforms: Sale of sequencing instruments including the AXELIOS 1 platform (in development) and AVENIO Edge System automation hardware for IVD and research use.
  2. Sequencing Reagents and Kits: KAPA library preparation kits, target enrichment panels, and AVENIO CGP assay kits sold as recurring consumables for NGS workflows.
  3. Software Licenses: Cloud-based software solutions including navify Mutation Profiler, FoundationOne Analysis Platform, and AVENIO Oncology Analysis Software for data analysis.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Roche Sequencing product offering

Product offering

Core offering

Roche Sequencing sells an end-to-end next-generation sequencing (NGS) portfolio covering KAPA DNA/RNA library preparation kits, KAPA target enrichment panels and probes, the AVENIO Edge System for automated sample prep, AVENIO comprehensive genomic profiling assays for oncology research, cloud-based analysis software (navify Mutation Profiler, AVENIO Oncology Analysis Software, FoundationOne Analysis Platform), and the in-development AXELIOS 1 Sequencing Platform based on its proprietary Sequencing by Expansion (SBX) chemistry. Products are sold as instruments, recurring reagent/consumable kits, and software licenses to research institutions, clinical laboratories, and pharmaceutical companies worldwide.

Product overview

Roche Sequencing offers a comprehensive portfolio of next-generation sequencing (NGS) solutions organized into integrated modules covering the entire sequencing workflow from sample preparation to data analysis. The portfolio is anchored by the KAPA library preparation and target enrichment solutions for efficient sample prep, the AVENIO Edge System for walk-away automation, AVENIO comprehensive genomic profiling (CGP) assays for oncology research, the AXELIOS 1 Sequencing Platform powered by proprietary Sequencing by Expansion (SBX) technology, and cloud-based data analysis tools including navify Mutation Profiler, AVENIO Oncology Analysis Software, and FoundationOne Analysis Platform. The AXELIOS 1 platform, based on innovative SBX technology, is designed to deliver unprecedented speed and flexibility for research applications. Third-party partnerships enable integration with external analysis platforms and liquid handling systems.

Differentiator

Problem solved

Functional benefit

Brands

  • KAPA: KAPA library preparation and target enrichment solutions for NGS workflows, including KAPA EvoPrep Kits, KAPA EvoPlus Kits, KAPA RNA EvoPrep Kits, and KAPA HyperExome V2 Probes.
  • AVENIO
  • AXELIOS
  • navify
  • FoundationOne

Products and services

  • KAPA EvoPrep Kits NGS library preparation kits that enable pre-fragmented DNA library preparation for whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted sequencing, and methyl-seq with a streamlined, fully automatable workflow. Targeted at research and clinical laboratories performing NGS workflows.
  • KAPA EvoPlus Kits High-performance DNA library preparation kits with enhanced enzymatic fragmentation and a streamlined, fully automatable workflow, for laboratories requiring reliable NGS library prep.
  • KAPA RNA EvoPrep Kits RNA library preparation kits designed to shorten workflow, boost sequencing efficiency, capture more unique transcripts, and accelerate RNA-based discovery research for genomics laboratories.
  • KAPA HyperExome V2 Probes and Kits Whole Exome Sequencing target enrichment probe and kit solution delivering superior content coverage for WES applications in research and clinical genomics.
  • HyperDesign Custom design tool for KAPA Target Enrichment workflows, combining KAPA target enrichment chemistry with Roche's probe and primer design expertise to design custom NGS panels.
  • AVENIO Edge System Fully automated IVD liquid handler for end-to-end library preparation, target enrichment, quantification, normalization, and pooling, combining Roche NGS expertise with pre-analytical automation experience for clinical and research laboratories.
  • AVENIO Designer Intuitive, templated design software for rapid and flexible user-defined workflow deployment on the AVENIO Edge System, with tunable parameters and validated workflows.
  • AXELIOS 1 Sequencing Platform High-throughput, transformative Research Use Only (RUO) sequencing platform powered by Sequencing by Expansion (SBX) technology, delivering accurate, cost-effective sequencing across a wide range of research applications at unprecedented scale and speed. SBX-Fast workflow enables DNA sequencing from sample to VCF in approximately 5 hours.
  • navify Mutation Profiler Research use only cloud-based software for interpretation of genomic alterations and signatures generated from sequencing DNA isolated from FFPE tumor tissue and liquid biopsy specimens, annotating somatic alterations with information from curated literature, databases, guidelines, drug labels, and clinical trials.
  • AVENIO Tumor Tissue CGP Kit V2 In-house next-generation sequencing (NGS) research assay providing comprehensive genomic profiling of solid tumors from formalin-fixed tissue specimens for oncology research.
  • AVENIO Tumor Tissue CGP Automated Kit Next-generation sequencing (NGS) assay for comprehensive genomic profiling (CGP) of solid tumors with automated workflow on the AVENIO Edge System for oncology research laboratories.
  • AVENIO ctDNA Expanded Kit V2 NGS liquid biopsy research assay for lung cancer, colorectal cancer, and pan-cancer research using circulating tumor DNA from plasma.

Quantifiable outcome

  • SBX-Fast workflow enables DNA sequencing from sample to VCF in approximately 5 hours
  • +2 more outcomes

Companies that use Roche Sequencing

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Roche Sequencing technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature7 records

Roche Sequencing partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Volta LabscoreTechnology or Integration · 26 February 2026Volta Labs announced integration of its Callisto platform with Roche Sequencing's AXELIOS 1 system at AGBT 2026. The integration enables automated genomics workflows combining Callisto's automation capabilities with Roche's SBX sequencing technology. UMC Utrecht and Hartwig Medical Foundation presented production-scale validation data showing thousands of patient samples processed with improved consistency and operational efficiency over nearly a year of deployment.
  • Watchmaker GenomicsminorStrategic or Co-development Partner · 26 February 2026Launched a PCR-free whole genome sequencing kit developed in collaboration with Watchmaker Genomics, expanding the ecosystem of solutions available for the Callisto platform and AXELIOS 1 system.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Roche Sequencing competitors and assessment

Company assessment

Direct peers

  • Illumina: Dominant short-read NGS platform provider (NovaSeq, NextSeq, iSeq) with a full sequencing-by-synthesis workflow; directly competes with Roche Sequencing's AXELIOS 1 and KAPA/AVENIO consumables for research and clinical lab customers.
  • Thermo Fisher Scientific: Operates the Ion Torrent sequencing platform plus an extensive NGS reagents and target-enrichment portfolio (Ion AmpliSeq, Oncomine); competes head-to-head with Roche across sequencing instruments, library prep, and oncology assays.
  • Element Biosciences: Developer of the AVITI benchtop NGS platform using an alternative sequencing chemistry; targets many of the same translational and clinical research labs that Roche's AXELIOS 1 and KAPA reagents are pursuing.
  • Singular Genomics: Provides the G4 benchtop NGS sequencer with a unique four-flow-cell architecture, competing directly with Roche's modular/flexible sequencing pitch to mid-throughput research customers.
  • Pacific Biosciences: Long-read sequencing platform (Revio, Onso) now expanding into short-read oncology research, increasingly competing with Roche's NGS assays and AXELIOS 1 across translational genomics.
  • Oxford Nanopore Technologies: Long-read/native nucleic acid sequencing platform (PromethION, GridION) competing for translational and clinical research applications where Roche's KAPA HyperExome and AXELIOS 1 also compete for share.

Broad incumbents

  • QIAGEN: Diversified sample-prep and molecular diagnostics provider (QIAseq target enrichment, GeneReader) overlapping with Roche's KAPA library prep, AVENIO assays, and bioinformatics offering.
  • Bio-Rad Laboratories: Provides Droplet Digital PCR and life science research tools with adjacent NGS workflows; competes at the bench-research and translational lab level where Roche sells KAPA reagents.

Emerging players

  • Ultima Genomics: Early-stage sequencing platform targeting ultra-low-cost high-throughput sequencing, positioning against AXELIOS 1 in the large-scale genomics research market.
  • MGI Tech (BGI Group): Provides DNBSEQ sequencing platforms and related reagents with broad global (especially APAC) reach; competes with Roche Sequencing instruments and consumables in international markets.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Roche Sequencing social profiles

Digital presence

Roche Sequencing financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roche Sequencing leadership team

Management profile

Number of profiles

Roche Sequencing funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roche Sequencing M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Sequencing

What does Roche Sequencing do?

Roche Sequencing sells an end-to-end next-generation sequencing (NGS) portfolio covering KAPA DNA/RNA library preparation kits, KAPA target enrichment panels and probes, the AVENIO Edge System for automated sample prep, AVENIO comprehensive genomic profiling assays for oncology research, cloud-based analysis software (navify Mutation Profiler, AVENIO Oncology Analysis Software, FoundationOne Analysis Platform), and the in-development AXELIOS 1 Sequencing Platform based on its proprietary Sequencing by Expansion (SBX) chemistry. Products are sold as instruments, recurring reagent/consumable kits, and software licenses to research institutions, clinical laboratories, and pharmaceutical companies worldwide.

Is Roche Sequencing a public or private company?

Roche Sequencing is a public company. It is classified as public and is currently operating.

When was Roche Sequencing founded?

Roche Sequencing was founded in 1896. It employs 101 to 250 people.

Where is Roche Sequencing based?

Roche Sequencing is headquartered in Indianapolis, United States, in the North America region.

How does Roche Sequencing make money?

Three revenue lines are on record. NGS Instruments and Platforms are the primary driver. The others are sequencing Reagents and Kits and software Licenses.

Who are Roche Sequencing's main competitors?

Direct peers on record are Illumina, Thermo Fisher Scientific, Element Biosciences, Singular Genomics, Pacific Biosciences and Oxford Nanopore Technologies. Broad incumbents are QIAGEN and Bio-Rad Laboratories. Emerging players are Ultima Genomics and MGI Tech (BGI Group).

Does Roche Sequencing have an API?

No public API is recorded for Roche Sequencing.

What industry is Roche Sequencing in?

Roche Sequencing's product category is Next-Generation Sequencing Solutions. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScienmagDonor-Specific Assemblies Reveal True Sequencing Error Profiles AcrossResearchers benchmarked nine short-read chemistries across seven DNA sequencers using donor-specific assemblies, isolating platform-intrinsic errors from biological variation. Element AVITI UltraQ and Roche SBX-D showed the lowest substitution error rates, and donor-specific references proved essential for unbiased base-quality recalibration.NaverMacrogen adopts Roche's next-gen platform to speed up genome sequencingMacrogen began operating Roche's Axelios 1 sequencing platform at its Songdo Global Genome Center in Incheon on Wednesday. The system uses Sequencing by Expansion technology to process DNA into Xpandomers, enabling faster and larger-scale genomic analysis. Macrogen plans to integrate it with its AI and automation systems to support population-scale studies.The Korea HeraldMacrogen adopts Roche's next-gen platform to speed up genome sequencingMacrogen began operating Roche's Axelios 1 sequencing platform at its Songdo Global Genome Center in Incheon. The system uses Sequencing by Expansion technology, enabling high-accuracy sequencing and greater data throughput. Macrogen plans to integrate it with existing automation and AI to speed up results and support large-scale genomic studies.GenengnewsExpanding the Possibilities of Next-Generation SequencingRoche's AXELIOS 1 platform uses sequencing by expansion (SBX) to physically expand DNA into Xpandomers for clearer base detection. It offers configurable batch sizes, read lengths up to ~1,500 bp, and same-day whole genome sequencing. The platform supports WGS, RNA-seq, single-cell, and methylation studies.Lab ManagerMaking High-Performance Sequencing More AccessibleRoche's AXELIOS 1 sequencing platform uses sequencing-by-expansion (SBX) with a surrogate molecule to achieve high-speed, high-quality sequencing. It offers duplex and simplex modes for accuracy and throughput, and can process 16 samples in a routine run or queue 64. The company plans to continue building the ecosystem for clinical research and diagnostic applications.ForbesRecord-Breaking Genome Sequencing Brings Same-Day Diagnosis To NewbornsResearchers at Boston Children's Hospital, Broad Clinical Labs, and Roche Sequencing Solutions completed whole genome sequencing and analysis in under four hours, setting a Guinness World Record. The method, using Roche's Sequencing by Expansion technology, could enable same-day diagnosis for critically ill newborns in NICUs. The team is now scaling the process and exploring applications in adult intensive care and infectious disease diagnostics.LinkedInCongenica acquired by SeqOne, creating global AI genomics leaderBroad Clinical Labs, in partnership with Roche Sequencing Solutions and Boston Children's Hospital, has set a Guinness World Record for the fastest whole human genome sequencing, completing the process in under 4 hours. This breakthrough enables same-day genomic diagnostics, significantly reducing the time required for actionable genetic insights from days to hours. The achievement utilizes Roche's new SBX sequencing technology within an integrated workflow, potentially transforming urgent care in neonatal and pediatric intensive care units.openPR.comAutomated Dna Sequencers Market Size by Type, Application, and Regional OutlookThe global automated DNA sequencers market is projected to grow from 2025 to 2032, driven by biotechnology advances, personalized medicine, and genomic research. North America and Asia-Pacific are expected to lead, with key players including Roche, Illumina, and Thermo Fisher. Challenges include high initial costs and regulatory complexity.GlobeNewswireRoche unveils a new class of next-generation sequencing with its novel sequencing by expansion technologyRoche unveiled its sequencing by expansion (SBX) technology on 20 February 2025, a new next-generation sequencing approach using expanded synthetic molecules and a CMOS sensor module. The technology reduces sample-to-genome time from days to hours and aims to accelerate genomic research and clinical applications.GlobeNewswireCodexis Announces License Agreement with Roche for Enzyme Used in Next Generation SequencingCodexis announced a license agreement with Roche to provide its EvoT4 DNA ligase enzyme for Roche's next-generation sequencing library preparation kits. The enzyme, developed with Codexis' CodeEvolver platform, is expected to improve ligation efficiency and sequencing sensitivity. The deal marks Codexis' first product targeting genomic sequencing.